ACC.08 Late Breaking Clinical Trials Document Advancements In Medical Device Research, Underscore Medtronic Leadership In Clinical Evidence

As ACC.08, the annual congress of the American College of Cardiology nears its close, Medtronic Inc. (NYSE: MDT) reaffirms its commitment to clinical evidence supporting the full range of implantable cardiac device therapy as standard of care for patients with heart failure, arrhythmias and those at risk of sudden cardiac arrest (SCA).

More: continued here

Filed under: Cardiovascular on April 2nd, 2008